The prophylactic effect of Hydroxychloroquine on Novel Corona virus

Phase 3

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20151222025660N2
• Lead Sponsor: Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

consent to participate in the study
People working in medical centers in Arak city
Lack of sensitivity to hydroxychloroquine
Lack of G6PD
Lack of porphyria
No breastfeeding
No pregnancy
Lack of diabetes, kidney , liver and skin disease

Exclusion Criteria

Lack of desire to continue studying
Having major side effects from medication

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of confirmed cases. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;Serum CRP levels and cellular immunity (cd8 / cd4 ratio) are assessed at the beginning and end of the study for all subjects. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.;The two groups will also be examined in terms of disease severity (need for intubation, ICU hospitalization) and absolute lymphocyte count. Timepoint: At the beginning and 2 months after the start of the study. Method of measurement: Checklist.